Sparfloxacin was more potent than other quinolones (tosufloxacin, lomefloxacin, ciprofloxacin, ofloxacin, fleroxacin, enoxacin, and norfloxacin) and as potent as minocycline and doxycycline in activity against Chlamydia trachomatis in vitro and in vivo. Sparfloxacin was more bactericidal than minocycline against C. trachomatis D/UW-3/Cx.
Chlamydia trachomatis is an important pathogen causing various urogenital and ophthalmic infections (14) . Tetracyclines have been used frequently for chlamydial infections for many years, although they have some undesirable side effects. Recently, some new quinolones have been reported to have antichlamydial activity in vitro (1, 7, 9, 16) , and some of them have successfully been applied to chlamydial infections in humans (2, 3) . Sparfloxacin has been reported to have potent antichlamydial activity (10) , but its position in antichlamydial chemotherapy remains uncertain because of the relatively few comparative data available. In the current study, we tested antichlamydial activities of sparfloxacin in vitro and in vivo in comparison with other quinolones and tetracyclines.
(Parts of this study were presented at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989 [11] .) Sparfloxacin and enoxacin were provided by Dainippon Pharmaceutical Co., tosufloxacin was provided by Toyama Chemical Co., lomefloxacin was provided by Hokuriku Seiyaku Co., ciprofloxacin was provided by Bayer Yakuhin Co., ofloxacin was provided by Daiichi Seiyaku Co., norfloxacin and fleroxacin were provided by Kyorin Pharmaceutical Co., and minocycline and doxycycline were provided by Lederle Japan Co. All the drugs were dissolved in sterile distilled water with or without NaOH for in vitro studies and dissolved or suspended in 0.2% carboxymethyl cellulose for in vivo ones.
Twenty-five clinical strains were isolated from patients who attended our clinic. C. trachomatis D/UW-3/Cx was supplied by National Institute of Health, Tokyo, Japan. C. trachomatis KN (serovar E) was a clinical isolate from a patient suffering from nongonococal urethritis (11) . The MIC was determined by the inhibition of inclusion body formation in McCoy cells, as described previously (7), except with 5% fetal bovine serum instead of 10%. The MBC was determined by inability to produce inclusion bodies in the drugfree medium. The McCoy cells cultured with drugs at or above their MICs were washed twice with the drug-free growth medium and suspended in 0.2 ml of the same * Corresponding author.
medium. Fresh 24-h-old McCoy cell monolayers were inoculated with 0.1 ml of the cell suspensions, cultured in the drug-free test medium, fixed and stained. The MBC was defined as the lowest drug concentration at which no inclusion bodies were detected at all throughout five serial passages in the drug-free medium. In vivo activities of drugs were assessed in a urogenital infection model in leukopenic mice (11) . Female 6-to 8-week-old Jcl-ICR mice (CLEA Japan Inc.) weighing 23 to 25 g were intraperitoneally injected with cyclophosphamide (Shionogi & Co.) at a dose of 300 mg/kg of body weight 48 h before chlamydial inoculation. Groups of five to six cyclophosphamide-induced leukopenic mice were intravenously anesthetized with sodium pentobarbital (Dainippon Pharmaceutical Co.) at a dose of 25 mg/kg, forced to void urine from the bladder by compressing gently the abdominal wall, and transurethrally inoculated into the bladder with 0.1 ml of a C. trachomatis KN suspension (2 x 105 inclusion-forming units per mouse) by using a tuberculin syringe with a blunt-end 23-gauge needle. The external urethral meatus of the mice was clamped with a clip for 5 h after inoculation, and they were refrained from drinking water for 24 h. Drugs were orally administered to them six times: 3, 8, 24, 30, 48, and 54 h after inoculation. On day 5 postinoculation, the mice were sacrificed under ether anesthesia. Their urinary bladders were exposed through a small suprapubic incision, opened, and rubbed with cotton swabs. The bladder mucous membrane in the swabs was suspended in 0.5 ml of a cold sucrosephosphate-glutamate medium (sucrouse, 75 g; KH2PO4, 0.52 g; Na2HPO4, 1.22 g; L-glutamic acid, 0.72 g; and distilled water, 1,000 ml) containing gentamicin (10 ,ug/ml) and amphotericin B (2 ,ug/ml) and stored at -70°C until cultivation. Fresh 24-h-old McCoy cell monolayers were inoculated with 0.25 ml of the thawed membrane suspensions and cultured in the drug-free medium as described in the MBC determination. No finding of inclusion bodies in the primary culture was regarded as being protected from chlamydial infection. The 50% effective dose (ED50) was calculated by probit analysis (8) and a 95% confidence limit by the method of Litchfield and Wilcoxon (6) .
Susceptibility of 25 clinical isolates of C. trachomatis to quinolones and tetracyclines is shown in Table 1 . The MICs for 90% of the strains tested (MIC90s) of sparfloxacin, This study was supported by a grant from Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.
